Understanding EMPA-REG OUTCOME
- 1 December 2015
- journal article
- other
- Published by Elsevier BV in The Lancet Diabetes & Endocrinology
- Vol. 3 (12), 929-930
- https://doi.org/10.1016/s2213-8587(15)00426-x
Abstract
No abstract availableKeywords
Funding Information
- Janssen Pharmaceuticals
- Sanofi
- Merck Sharp and Dohme
- Unilever
- AstraZeneca España
- Eli Lilly and Company
- Boehringer Ingelheim España
- Novartis
- Novo Nordisk
- Takeda Pharmaceutical Company
- Servier
This publication has 7 references indexed in Scilit:
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine, 2015
- Getting to the heart of the matter in type 2 diabetesThe Lancet Diabetes & Endocrinology, 2015
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine, 2015
- Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: A meta-analysisInternational Journal of Cardiology, 2015
- Dipeptidyl peptidase IV inhibitors: a new paradigm in type 2 diabetes treatment.Current Drug Targets, 2014
- Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patientsJCI Insight, 2014
- Minireview: Glucagon in Stress and Energy HomeostasisEndocrinology, 2012